Summary of LPL
LPL encodes for the enzyme lipoprotein lipase. It plays a role in breaking down fat in the form of triglycerides. When lipoprotein lipase breaks down triglycerides, the fat molecules are used by the body as energy or stored in fatty tissue for later use (R).
Mutations in this can cause familial lipoprotein lipase deficiency, which will lead to an increase in fat and cause inflammation (R).
The Function of LPL
The primary function of this lipase is the hydrolysis of triglycerides of circulating chylomicrons and very low density lipoproteins (VLDL). Binding to heparin sulfate proteogylcans at the cell surface is vital to the function. The apolipoprotein, APOC2, acts as a coactivator of LPL activity in the presence of lipids on the luminal surface of vascular endothelium.
Protein names
Recommended name:
Lipoprotein lipaseShort name:
LPL- RS10096633 (LPL) ??
- RS10105606 (LPL) ??
- RS10503669 (LPL) ??
- RS1059611 (LPL) ??
- RS115849089 (LPL) ??
- RS12678919 (LPL) ??
- RS13702 (LPL) ??
- RS1441756 (LPL) ??
- RS15285 (LPL) ??
- RS17091905 (LPL) ??
- RS17410962 (LPL) ??
- RS17482753 (LPL) ??
- RS1800590 (LPL) ??
- RS2083637 (LPL) ??
- RS2197089 (LPL) ??
- RS263 (LPL) ??
- RS264 (LPL) ??
- RS268 (LPL) ??
- RS285 (LPL) ??
- RS295 (LPL) ??
- RS301 (LPL) ??
- RS320 (LPL) ??
- RS3200218 (LPL) ??
- RS325 (LPL) ??
- RS326 (LPL) ??
- RS328 (LPL) ??
- RS331 (LPL) ??
- RS7016880 (LPL) ??
- RS7816032 (LPL) ??
- RS7841189 (LPL) ??
- RS79236614 (LPL) ??
- RS9644568 (LPL) ??
To see your genotype, you should be logged in and have a file with your genotype uploaded.
Top Gene-Substance Interactions
LPL Interacts with These Diseases
Disease | Score |
Substances That Increase LPL
Substances | Interaction | Organism | Category |
Substances That Decrease LPL
Substances | Interaction | Organism | Category |
Advanced Summary
LPL encodes for the enzyme lipoprotein lipase. It plays a role in breaking down fat in the form of triglycerides. When lipoprotein lipase breaks down triglycerides, the fat molecules are used by the body as energy or stored in fatty tissue for later use (R).
Mutations in this can cause familial lipoprotein lipase deficiency, which will lead to an increase in fat and cause inflammation (R).
familial lipoprotein lipase deficiency More than 220 mutations in the LPL gene have been found to cause familial lipoprotein lipase deficiency. This condition disrupts the normal breakdown of triglycerides in the body, resulting in an increase of these fats. The most common mutation in people of European ancestry replaces the protein building block (amino acid) glycine with the amino acid glutamic acid at position 188 in the enzyme (written as Gly188Glu or G188E). Mutations that cause familial lipoprotein lipase deficiency reduce or eliminate lipoprotein lipase activity, which prevents the enzyme from effectively breaking down triglycerides in the bloodstream. As a result, triglycerides attached to lipoproteins accumulate in the blood and tissues, leading to inflammation of the pancreas (pancreatitis), enlarged liver and spleen (hepatosplenomegaly), fatty deposits in the skin (eruptive xanthomas), and the other signs and symptoms of familial lipoprotein lipase deficiency. other disorders Certain variations in the LPL gene have been shown to influence the levels of fats in the bloodstream. The LPL gene variants likely result in the production of lipoprotein lipase enzymes with altered abilities to break down triglycerides. In some cases, the enzyme is overactive, resulting in low fat levels. In other cases, the enzyme is impaired, resulting in increased fat levels, a condition called hyperlipidemia. Individuals with hyperlipidemia are at greater than normal risk of developing atherosclerosis, a condition in which fatty deposits accumulate on artery walls. This fatty material hardens over time, eventually blocking the arteries and increasing the chance of having a heart attack or stroke. It is unclear how much of a role LPL gene variants play in the development of atherosclerosis, as a large number of genetic and environmental factors determine the risk of developing this complex condition.
The LPL gene provides instructions for making an enzyme called lipoprotein lipase . This enzyme is found primarily on the surface of cells that line tiny blood vessels (capillaries) within muscles and in fatty (adipose) tissue. Lipoprotein lipase plays a critical role in breaking down fat in the form of triglycerides, which are carried from various organs to the blood by molecules called lipoproteins. Lipoprotein lipase breaks down triglycerides carried by two different types of lipoproteins, which bring fat to the bloodstream from different organs. Fat from the intestine, which is taken in from the diet, is transported to the bloodstream by lipoproteins called chylomicrons. Another type of lipoprotein called very low density lipoprotein (VLDL) carries triglycerides from the liver to the bloodstream. When lipoprotein lipase breaks down triglycerides, the fat molecules are used by the body as energy or stored in fatty tissue for later use.
Conditions with Increased Gene Activity
Condition | Change (log2fold) | Comparison | Species | Experimental variables | Experiment name |
---|
Conditions with Decreased Gene Activity
Condition | Change (log2fold) | Comparison | Species | Experimental variables | Experiment name |
---|
Technical
The following transcription factors affect gene expression:
Gene Pathways:
Molecular Function:
- Apolipoprotein Binding
- Heparin Binding
- Lipoprotein Lipase Activity
- Phospholipase Activity
- Receptor Binding
- Triglyceride Binding
- Triglyceride Lipase Activity
Biological Processes:
- Cholesterol Homeostasis
- Chylomicron Remodeling
- Fatty Acid Biosynthetic Process
- Lipoprotein Metabolic Process
- Phospholipid Metabolic Process
- Positive Regulation Of Chemokine Secretion
- Positive Regulation Of Cholesterol Storage
- Positive Regulation Of Inflammatory Response
- Positive Regulation Of Macrophage Derived Foam Cell Differentiation
- Positive Regulation Of Sequestering Of Triglyceride
- Response To Cold
- Response To Glucose
- Retinoid Metabolic Process
- Triglyceride Biosynthetic Process
- Triglyceride Catabolic Process
- Triglyceride Homeostasis
- Triglyceride Metabolic Process
- Very-Low-Density Lipoprotein Particle Remodeling
Drug Bank:
- Ast-120
- Tyloxapol